Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease.

Next Previous
Trial Profile

A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donepezil (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 13 Dec 2017 According to an Eisai media release, based on the results from this trial, Aricept (donepezil hydrochloride) has been approved for the additional indication of severe Alzheimer's disease in China.
    • 30 Sep 2014 Top-line results published in an Eisai media release. Based on the results of this trial, an application will be made to Chinese regulatory authorities to extend the indications for donepezil to include severe Alzheimer's disease.
    • 30 Sep 2014 Primary endpoint has been met (Change in total Severe Impairment Battery score at Week 24; significant superiority of donepezil vs placebo), according to an Eisai media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top